Liquidia Settles All UTC Litigation for $380.7M, Preserves YUTREPIA PAH Franchise
Summary
Liquidia settled all litigation with United Therapeutics for $380.7 million net, preserving YUTREPIA's PAH indication while removing PH-ILD from the label. The company disclosed strong preliminary Q3 sales of $222.7 million and $396.1 million in cash to fund the payments. Shares jumped 42% after the settlement, and Liquidia agreed not to appeal the September 30 court ruling.
Updated with a dpa-AFX report · What changed
Updates
· dpa-AFX — Liquidia shares rose 46.10% to $39.17 in overnight trading after the settlement.
- Settlement Terms — The settlement followed a September 30, 2026, ruling that two United Therapeutics patent claims were valid and infringed. Liquidia agreed not to appeal.
- Antitrust Settlement — The $175 million net payment reflects UTHR's payments to Liquidia to settle antitrust litigation related to Treprostinil Injection. Liquidia terminated its promotional agreement associated with Treprostinil Injection and will no longer provide commercial support.
All 4 details
- The settlement followed a September 30, 2026, ruling by the U.S. District Court for the District of Delaware that two United Therapeutics patent claims were valid and that Liquidia infringed them.
- Liquidia has agreed not to appeal the court's ruling.
- The $175 million net payment reflects UTHR's payments to Liquidia to settle antitrust litigation related to Treprostinil Injection.
- Liquidia terminated its promotional agreement associated with Treprostinil Injection and will no longer provide commercial support for the product.
· Seeking Alpha — Liquidia shares jumped 42% after the settlement; it will pay $60.3M this month to antitrust parties and reported preliminary Q3 YUTREPIA sales of $222.7M.
- Two $72.7 million installments are due by January 31 and April 30, 2027.
- Liquidia agreed not to appeal the September 30 court ruling.
Key Events · Legal and Risk Events · LQDA
-
New · · dpa-AFX
Treprostinil Injection Promotional Agreement Terminated
Liquidia terminated its promotional agreement associated with Treprostinil Injection and will no longer provide commercial support for the product.
-
New · · dpa-AFX
Stock Surge After Settlement
Liquidia shares jumped 42% after the settlement, and rose 46.10% to $39.17 in overnight trading.
-
New · · dpa-AFX
September 30 Court Ruling
The settlement followed a September 30, 2026, ruling by the U.S. District Court for the District of Delaware that two United Therapeutics patent claims were valid and that Liquidia infringed them.
-
Updated · · dpa-AFX
Global Settlement with United Therapeutics
Liquidia agreed to pay $380.7 million net to UTC to resolve all six pending lawsuits, including patent infringement, trade secret, and antitrust claims. YUTREPIA remains available for PAH patients without disruption. Liquidia agreed not to appeal the September 30 court ruling.
-
Updated · · dpa-AFX
Payment Structure and Timeline
$175.0 million net due within 30 business days, plus $145.4 million in two equal installments of $72.7 million due January 31, 2027 and April 30, 2027. Additional $60.3 million to Sandoz, Henderson, and PBM this month. The $175 million net payment reflects UTHR's payments to Liquidia to settle antitrust litigation related to Treprostinil Injection.
-
PH-ILD Indication Removed
Liquidia must file with FDA to remove PH-ILD from YUTREPIA's label and immediately cease all marketing, promotion, and detailing for PH-ILD. The company will continue selling YUTREPIA for PAH only.
-
Financing Covenant Tightened
Seventh Amendment to HCR Revenue Interest Financing Agreement increases minimum cash covenant from $15.0 million to $45.0 million in exchange for consent to issue a letter of credit for the settlement.
Analysis · LQDA · Life Sciences
Resolving all six lawsuits with United Therapeutics for $380.7 million net removes the existential threat to Liquidia's YUTREPIA franchise. The company retains the right to sell YUTREPIA for PAH but must strip the PH-ILD indication from the label. Funding the settlement are strong Q3 sales of $222.7 million and $396.1 million in cash, though the $45 million minimum cash covenant with HCR and the $60.3 million in related-party payouts this month will pressure near-term liquidity. The deal eliminates a major overhang that had driven the stock down 25% after the September 30 adverse patent ruling, and shares jumped 42% after the settlement. Liquidia agreed not to appeal the September 30 court ruling, which found two United Therapeutics patent claims valid and infringed.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 44.1% of the 299 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $39.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.